Targeted therapies for the treatment of soft tissue sarcoma
Soft tissue sarcomas are rare malignant tumors derived from mesenchymal cells that have a high morbidity and mortality related to frequent occurrence of advanced and metastatic disease. Over the past two decades there have been significant advances in the use of targeted therapies for the treatment...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1122508/full |
| _version_ | 1811157809020010496 |
|---|---|
| author | Jeffrey W. Fuchs Brian C. Schulte Joseph R. Fuchs Mark Agulnik |
| author_facet | Jeffrey W. Fuchs Brian C. Schulte Joseph R. Fuchs Mark Agulnik |
| author_sort | Jeffrey W. Fuchs |
| collection | DOAJ |
| description | Soft tissue sarcomas are rare malignant tumors derived from mesenchymal cells that have a high morbidity and mortality related to frequent occurrence of advanced and metastatic disease. Over the past two decades there have been significant advances in the use of targeted therapies for the treatment of soft tissue sarcoma. The ability to study various cellular markers and pathways related to sarcomagenesis has led to the creation and approval of multiple novel therapies. Herein, we describe the current landscape of targeted medications used in the management of advanced or metastatic soft tissue sarcomas, excluding GIST. We distinguish three categories: targeted therapies that have current US Food and Drug Administration (FDA) approval for treatment of soft tissue sarcoma, non-FDA approved targeted therapies, and medications in development for treatment of patients with soft tissue sarcoma. |
| first_indexed | 2024-04-10T05:13:40Z |
| format | Article |
| id | doaj.art-4f42554425ac4b52865b21d97690c086 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T05:13:40Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4f42554425ac4b52865b21d97690c0862023-03-09T05:47:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11225081122508Targeted therapies for the treatment of soft tissue sarcomaJeffrey W. Fuchs0Brian C. Schulte1Joseph R. Fuchs2Mark Agulnik3Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, United StatesDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United StatesDepartment of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, United StatesMedical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, United StatesSoft tissue sarcomas are rare malignant tumors derived from mesenchymal cells that have a high morbidity and mortality related to frequent occurrence of advanced and metastatic disease. Over the past two decades there have been significant advances in the use of targeted therapies for the treatment of soft tissue sarcoma. The ability to study various cellular markers and pathways related to sarcomagenesis has led to the creation and approval of multiple novel therapies. Herein, we describe the current landscape of targeted medications used in the management of advanced or metastatic soft tissue sarcomas, excluding GIST. We distinguish three categories: targeted therapies that have current US Food and Drug Administration (FDA) approval for treatment of soft tissue sarcoma, non-FDA approved targeted therapies, and medications in development for treatment of patients with soft tissue sarcoma.https://www.frontiersin.org/articles/10.3389/fonc.2023.1122508/fullsoft tissue sarcomatargeted therapytyrosine kinase inhibitorsclinical trialdrug therapy |
| spellingShingle | Jeffrey W. Fuchs Brian C. Schulte Joseph R. Fuchs Mark Agulnik Targeted therapies for the treatment of soft tissue sarcoma Frontiers in Oncology soft tissue sarcoma targeted therapy tyrosine kinase inhibitors clinical trial drug therapy |
| title | Targeted therapies for the treatment of soft tissue sarcoma |
| title_full | Targeted therapies for the treatment of soft tissue sarcoma |
| title_fullStr | Targeted therapies for the treatment of soft tissue sarcoma |
| title_full_unstemmed | Targeted therapies for the treatment of soft tissue sarcoma |
| title_short | Targeted therapies for the treatment of soft tissue sarcoma |
| title_sort | targeted therapies for the treatment of soft tissue sarcoma |
| topic | soft tissue sarcoma targeted therapy tyrosine kinase inhibitors clinical trial drug therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1122508/full |
| work_keys_str_mv | AT jeffreywfuchs targetedtherapiesforthetreatmentofsofttissuesarcoma AT briancschulte targetedtherapiesforthetreatmentofsofttissuesarcoma AT josephrfuchs targetedtherapiesforthetreatmentofsofttissuesarcoma AT markagulnik targetedtherapiesforthetreatmentofsofttissuesarcoma |